These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17488736)

  • 1. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study.
    Calvert MJ; McManus RJ; Freemantle N
    Fam Pract; 2007 Jun; 24(3):224-9. PubMed ID: 17488736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.
    Calvert MJ; McManus RJ; Freemantle N
    Br J Gen Pract; 2007 Jun; 57(539):455-60. PubMed ID: 17550670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
    Cook MN; Girman CJ; Stein PP; Alexander CM
    Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001.
    Lecomte P; Romon I; Fosse S; Simon D; Fagot-Campagna A
    Diabetes Metab; 2008 Jun; 34(3):219-26. PubMed ID: 18343703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of self-management education for patients with Type 2 diabetes taking maximal oral hypoglycaemic therapy: a randomized trial in primary care.
    Goudswaard AN; Stolk RP; Zuithoff NP; de Valk HW; Rutten GE
    Diabet Med; 2004 May; 21(5):491-6. PubMed ID: 15089797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study.
    Penfornis A; Bourdel-Marchasson I; Quere S; Dejager S
    Diabetes Metab; 2012 Dec; 38(6):550-7. PubMed ID: 22996038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal observational study of insulin therapy and glycaemic control in Scottish children with Type 1 diabetes: DIABAUD 3.
    Scottish Study Group for the Care of the Young with Diabetes
    Diabet Med; 2006 Nov; 23(11):1216-21. PubMed ID: 17054598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study.
    Halimi S; Balkau B; Attali C; Detournay B; Amelineau E; Blickle JF
    Diabetes Metab; 2012 Mar; 38 Suppl 3():S36-46. PubMed ID: 22541601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.
    Rubino A; McQuay LJ; Gough SC; Kvasz M; Tennis P
    Diabet Med; 2007 Dec; 24(12):1412-8. PubMed ID: 18042083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM; Bergstad I; Thorsby PM; Johannesen O; Solberg M; Birkeland KI
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
    Schweizer A; Couturier A; Foley JE; Dejager S
    Diabet Med; 2007 Sep; 24(9):955-61. PubMed ID: 17509069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.
    Currie CJ; Peters JR; Tynan A; Evans M; Heine RJ; Bracco OL; Zagar T; Poole CD
    Lancet; 2010 Feb; 375(9713):481-9. PubMed ID: 20110121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.